Asian Myeloproliferative Neoplasm (MPN) Registry

Key facts

Sponsor

The University of Hong Kong

Principal Investigator

Harinder Gill, MD

The University of Hong Kong

Enrollment

1000 enrolled

Eligibility

18 years · All sexes

Timeline

2023 – 2026

Study locations (1)

• Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong

Collaborators

Novartis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Essential thrombocythemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07469891
  A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
  Prelude Therapeutics
• RECRUITINGNCT06976918
  Registry Platform Myelofibrosis and Anemia
  iOMEDICO AG
• RECRUITINGNCT07203768
  A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
  FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
• RECRUITINGPHASE2NCT06517875
  Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
  GlaxoSmithKline
• RECRUITINGNANCT06734637
  Efficacy and Safety of Peginterferon in ET and PV.
  Zhenya Hong
• RECRUITINGPHASE1NCT06343805
  A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
  Ajax Therapeutics, Inc.
• RECRUITINGPHASE2NCT06541249
  MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
  Icahn School of Medicine at Mount Sinai
• RECRUITINGPHASE2NCT06552429
  Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET
  Xiamen Amoytop Biotech Co., Ltd.

See all trials for Essential thrombocythemia →